Is Cartesian Therapeutics Inc halal to invest in?

As of July 2026, Cartesian Therapeutics Inc RNAC is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Cartesian Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Cartesian Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Cartesian Therapeutics Inc?

Muslim investors may consider investing in Cartesian Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Cartesian Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Cartesian Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Cartesian Therapeutics Inc updated?

The Shariah compliance status of Cartesian Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Cartesian Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Cartesian Therapeutics Inc?

You can check the latest Shariah compliance status of Cartesian Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

RNAC Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Cartesian Therapeutics Inc is classified as not halal.

NOT HALAL

Report Source: 2026 1st Quarter Report

Cartesian Therapeutics Inc. Stock Analysis RNAC

United States Health Care Small Cap Report: Q1, 2026

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in mRNA cell therapies for the treatment of autoimmune diseases. The company is headquartered in Frederick, Maryland and currently employs 75 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

Key Statistics of Cartesian Therapeutics Inc (RNAC)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$7.98$8.31

Today's Open

$8.07

Volume

86.54K

P/E Ratio (TTM)

52 Week Range

$5.60$14.56

Market Cap

301.16M

Avg. Volume

223.29K

Dividend Yield

Financial Metrics & Statements of Cartesian Therapeutics Inc (RNAC)

Super Investors Invested in Cartesian Therapeutics Inc (RNAC)

FAQ's for Cartesian Therapeutics Inc (RNAC)

As of July 2026, Cartesian Therapeutics Inc RNAC is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Cartesian Therapeutics Inc using these criteria to determine its compliance status.
Muslim investors may consider investing in Cartesian Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of Cartesian Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of Cartesian Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of Cartesian Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.